Lucy Day

CIK: 0001914510

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (27.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (45.5%)

Compensation grants

Other (G, F, J, C, D, …)3 (27.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ANTX

AN2 Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (right to buy)
Direct
82.3K shares-
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Award(A)
Stock Option (right to buy)
Direct
73.7K shares-
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (right to buy)
Direct
73.7K shares-
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Award(A)
Stock Option (right to buy)
Direct
66K shares-
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (right to buy)
Direct
66K shares-
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Award(A)
Stock Option (right to buy)
Direct
82.3K shares-
ANTX
AN2 Therapeutics, Inc.
Feb 20, 2026
Award(A)
Direct
38K shares-
ANTX
AN2 Therapeutics, Inc.
Jan 6, 2026
Sale(S)
Direct
5.5K shares at avg. $1.01$6K
ANTX
AN2 Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
3.3K shares at avg. $1.00$3K
ANTX
AN2 Therapeutics, Inc.
Feb 26, 2025
Award(A)
Direct
46.5K shares-
ANTX
AN2 Therapeutics, Inc.
Jan 3, 2025
Sale(S)
Direct
3K shares at avg. $1.34$4K

		Type	Shares	Price		Ownership
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	82,300	-	-	Direct
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Award(A) Stock Option (right to buy)	73,665	-	-	Direct
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	73,665	-	-	Direct
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Award(A) Stock Option (right to buy)	66,000	-	-	Direct
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	66,000	-	-	Direct
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Award(A) Stock Option (right to buy)	82,300	-	-	Direct
Feb 20, 2026	ANTX AN2 Therapeutics, Inc.	Award(A)	38,000	-	$0	Direct
Jan 6, 2026	ANTX AN2 Therapeutics, Inc.	Sale(S)	5,512	$1.01	$5,578	Direct
Jan 5, 2026	ANTX AN2 Therapeutics, Inc.	Sale(S)	3,295	$1.00	$3,305	Direct
Feb 26, 2025	ANTX AN2 Therapeutics, Inc.	Award(A)	46,500	-	-	Direct
Jan 3, 2025	ANTX AN2 Therapeutics, Inc.	Sale(S)	2,957	$1.34	$3,965	Direct

1-11 of 11 transactions

About Day Lucy

Day Lucy (SEC CIK 0001914510) files insider reports with the SEC as Chief Financial Officer of AN2 Therapeutics, Inc. (ANTX).

Signal8 holds 5 ownership filings by Day Lucy, all Form 4s, filed between Jan 7, 2025 and Mar 23, 2026. Those filings report 11 transactions, from Jan 3, 2025 to Mar 19, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Day Lucy's filings is in MENLO PARK, CA.

Recent filings by Day Lucy

Mar 19, 2026: Disposition to issuer transaction of ANTX derivative securities (Form 4, code D).
Mar 19, 2026: Grant or award of ANTX derivative securities (Form 4, code A).
Mar 19, 2026: Disposition to issuer transaction of ANTX derivative securities (Form 4, code D).
Mar 19, 2026: Grant or award of ANTX derivative securities (Form 4, code A).
Mar 19, 2026: Disposition to issuer transaction of ANTX derivative securities (Form 4, code D).

Other insiders filing for AN2 Therapeutics, Inc. (ANTX)

Marks Gilbert Lynn, Director
Martin Patricia A., Director
Aziz Kabeer, Director
Trenor Cameron C. III, Chief Medical Officer
Readnour Robin Shane, Director
Williams Sarah Joanne, Principal Accounting Officer

How to read Form 4 transaction codes